A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in @entity1 with chronic XXXX .

@entity1 @entity1931 @entity1372 @entity158 @entity9
Several lines of evidence suggest that @entity9 is mediated in part by an increase in the density of voltage-sensitive @entity1372 channels in injured axons and the dorsal root ganglion of injured axons. The purpose of this study was to examine the safety, analgesic efficacy, and tolerability of oral 4030W92 (a new novel @entity1372 channel blocker) in a group of subjects with chronic @entity9 . This study used a randomized, double-blind, placebo-controlled, crossover design in 41 subjects with @entity9 with a prominent @entity1931 . Each subject received a 2-week course of 4030W92 (25 mg/day) and placebo separated by a 2-week washout period. At baseline, postdose day 1, day 7, and day 14, the following were measured: (1) spontaneous and evoked @entity158 scores, (2) dynamic and static @entity1931 mapping, (3) Short Form McGill Pain Questionnaire, and (4) blood sample for 4030W92 assay. At baseline and day 14 the following were measured: (1) thermal testing in the @entity158 area, (2) Medical Outcomes Study Short Form 36 Questionnaire, and (3) @entity1 global satisfaction. Allodynia severity was significantly lower (P = .046) on treatment day 1, postdose for 4030W92 compared to placebo. However, this was not maintained on treatment day 7 or 14. The area of static @entity1931 was significantly smaller (P = .03) on treatment day 7 for 4030W92 compared to placebo. However, this was not maintained to treatment day 14. There was no significant effect of 4030W92 on any other efficacy measure. Side effects were minimal. 4030W92, at 25 mg/day, produced a nonsignificant @entity158 without treatment limiting side effects. The maximum analgesic effect of this drug remains unknown.
